Using MRI to Study Cancer Treatments
Author Information
Author(s): Leach M O, Brindle K M, Evelhoch J L, Griffiths J R, Horsman M R, Jackson A, Jayson G C, Judson I R, Knopp M V, Maxwell R J, McIntyre D, Padhani A R, Price P, Rathbone R, Rustin G J, Tofts P S, Tozer G M, Vennart W, Waterton J C, Williams S R, Workman P
Primary Institution: Cancer Research UK
Hypothesis
How can magnetic resonance imaging (MRI) be effectively used to assess antiangiogenic and antivascular therapies in early-stage clinical trials?
Conclusion
The workshop provided guidelines for using MRI to evaluate the effectiveness of antiangiogenic and antivascular therapies in cancer treatment.
Supporting Evidence
- Dynamic contrast-enhanced MRI is increasingly used to monitor cancer therapies noninvasively.
- Guidelines were developed to help researchers design MRI studies for evaluating cancer treatments.
- Functional imaging may provide earlier or more specific information than traditional imaging methods.
Takeaway
Doctors can use special pictures from MRI to see how well new cancer treatments are working without needing to do surgery.
Methodology
The publication summarizes discussions and recommendations from a workshop focused on MRI methodologies for evaluating cancer therapies.
Limitations
The effectiveness of MRI in early-stage trials may be limited by the maturity of the vascular phenotype in patients with advanced disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website